Reproductive biomedicine online · 2025
Impact of hormone replacement therapy on serum thyroid-stimulating hormone: a retrospective analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Molinaro Pietro, Pellegrini Livia, Mariani Giulia, Fasulo Diego D, Galliano Daniela, Pellicer Antonio, Cozzolino Mauro
Аннотация
RESEARCH QUESTION: What is the impact of hormone replacement therapy (HRT) on serum thyroid-stimulating hormone (TSH) during endometrial preparation for single-embryo transfer (SET)?
DESIGN: This retrospective cohort study included 516 women (≤49 years) who underwent SET with either autologous or donor oocytes, between January 2022 and January 2023 at IVI Rome. TSH was measured at baseline (T0), during endometrial thickness assessment (T1), on embryo transfer day (T2), and at the pregnancy test (T3). TSH >2.5 mU/l was treated with levothyroxine. HRT consisted of oral estradiol valerate (6 mg/day) followed by vaginal progesterone (800 mg/day).
RESULTS: TSH significantly increased at T1 and T3 compared to T0 (TSH0 1.67 mU/l, 95%CI 1.59-1.74; TSH1 1.93 mU/l, 95%CI 1.83-2.04, p < 0.001; TSH3 2.08 mU/l, 95%CI 1.97-2.18, p < 0.001). Univariate analysis showed that patients with a TSH < 2.5 mU/l at T3 had higher miscarriage rate (15.2%, 95%CI 10.8-20.6 vs 29.7%, 95%CI 19.7-41.4; p = 0.01) and lower ongoing pregnancy (65.8%, 95%CI 60-71.3 vs 49.5%, 95%CI 39.5-59.5; p = 0.005) and live birth rates (62.5%, 95%CI 56.3-68.3 vs 47.5%, 95%CI 37.3-57.8; p = 0.01). Multivariate analysis showed no significant association between TSH >2.5 mU/l and pregnancy (aOR 0.64, 95%CI 0.36-1.14, p=0.13) or miscarriage (aOR 1.78, 95%CI 0.87-3.66, p = 0.11), while negative association was observed between TSH >2.5 mU/l and live birth (aOR 0.54, 95%CI 0.32-0.92, p = 0.02).
CONCLUSIONS: HRT significantly increased TSH concentrations. Additionally, a TSH >2.5 mU/l did not correlate with miscarriage, but it was significantly associated with lower live birth rates. Further studies are needed to clarify HRT's impact on thyroid function and reproductive outcomes.
DESIGN: This retrospective cohort study included 516 women (≤49 years) who underwent SET with either autologous or donor oocytes, between January 2022 and January 2023 at IVI Rome. TSH was measured at baseline (T0), during endometrial thickness assessment (T1), on embryo transfer day (T2), and at the pregnancy test (T3). TSH >2.5 mU/l was treated with levothyroxine. HRT consisted of oral estradiol valerate (6 mg/day) followed by vaginal progesterone (800 mg/day).
RESULTS: TSH significantly increased at T1 and T3 compared to T0 (TSH0 1.67 mU/l, 95%CI 1.59-1.74; TSH1 1.93 mU/l, 95%CI 1.83-2.04, p < 0.001; TSH3 2.08 mU/l, 95%CI 1.97-2.18, p < 0.001). Univariate analysis showed that patients with a TSH < 2.5 mU/l at T3 had higher miscarriage rate (15.2%, 95%CI 10.8-20.6 vs 29.7%, 95%CI 19.7-41.4; p = 0.01) and lower ongoing pregnancy (65.8%, 95%CI 60-71.3 vs 49.5%, 95%CI 39.5-59.5; p = 0.005) and live birth rates (62.5%, 95%CI 56.3-68.3 vs 47.5%, 95%CI 37.3-57.8; p = 0.01). Multivariate analysis showed no significant association between TSH >2.5 mU/l and pregnancy (aOR 0.64, 95%CI 0.36-1.14, p=0.13) or miscarriage (aOR 1.78, 95%CI 0.87-3.66, p = 0.11), while negative association was observed between TSH >2.5 mU/l and live birth (aOR 0.54, 95%CI 0.32-0.92, p = 0.02).
CONCLUSIONS: HRT significantly increased TSH concentrations. Additionally, a TSH >2.5 mU/l did not correlate with miscarriage, but it was significantly associated with lower live birth rates. Further studies are needed to clarify HRT's impact on thyroid function and reproductive outcomes.